Emilia Scalzulli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study	BLOOD	2022
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?	JOURNAL OF CLINICAL MEDICINE	2022
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols	ACTA ONCOLOGICA	2021
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience	LEUKEMIA & LYMPHOMA	2021
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?	BLOOD REVIEWS	2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up	LEUKEMIA & LYMPHOMA	2021
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients	ANNALS OF HEMATOLOGY	2021
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2021
Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters	BRITISH JOURNAL OF HAEMATOLOGY	2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up	LEUKEMIA & LYMPHOMA	2021
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab	ANNALS OF HEMATOLOGY	2021
Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia	BLOOD	2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib	ANNALS OF HEMATOLOGY	2021
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors	EXPERT REVIEW OF HEMATOLOGY	2021
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients	ANNALS OF HEMATOLOGY	2021
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2021
Measuring prognosis in chronic myeloid leukemia: what's new?	EXPERT REVIEW OF HEMATOLOGY	2021
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols	ACTA ONCOLOGICA	2021
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A ``Campus CML{''} Study	BLOOD	2021
Hemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulants	AMERICAN JOURNAL OF THERAPEUTICS	2020